Brought to you by 
Cabrellis Pharmaceuticals raises $27.5mm in Series A round
24 Jun 2020
Executive Summary
Specialty pharma company Cabrellis Pharmaceuticals (cancer drugs; a spin-off of Conforma Therapeutics) raised $27.5mm from a Series A private financing. Investors included Domain Associates, Forward Ventures, Lilly Ventures, Novo AS, ProQuest Investments, RBC Capital Partners, RiverVest Venture Partners, and SR One Ltd.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cabrellis Pharmaceuticals raises $27.5mm in Series A round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice